General Medical issues thread

@prozac

It appears Xanamem is undergoing Phase 2 trials
There is still a long way to go

The big Phase 3 trial - where they test it on thousands of people is yet to be undertaken

There is another AD trial drug called Lecanemab (an antibody against the amyloid) which took, I think 5 years, for Phase 3. It is now approved by the TGA but not by the PBS meaning it costs about $40K a year.

Typically a Phase 3 might take 3-5 years, then 1 year for TGA approval and another year for PBS approval for concessional pricing.

Based on a quick look Specifically for Xanamem, it appears that the data suggest that while it has a eexcellent safety profile, it did not reach statistical significance for the study primary endpoint for the overall study population
. However in the older group >75yrs, there appears to be a slight benefit - a statistically significant 40% did not show disease progression compared with 22% in placebo. Other small benefits were not statistically significant.

They could do a larger study to get more statistical power for a longer period. 9 months is not very long to study Alzheimer treatment.

Consequently The phase 3 trial has been suspended and funding for it apparently withdrawn, and they may or may not be doing one for that older cohort.
 
Last edited:
@prozac

It appears Xanamem is undergoing Phase 2 trials
There is still a long way to go

The big Phase 3 trial - where they test it on thousands of people is yet to be undertaken

There is another AD trial drug called Lecanemab (an antibody against the amyloid) which took, I think 5 years, for Phase 3. It is now approved by the TGA but not by the PBS meaning it costs about $40K a year.

Typically a Phase 3 might take 3-5 years, then 1 year for TGA approval and another year for PBS approval for concessional pricing.

Based on a quick look Specifically for Xanamem, it appears that the data suggest that while it has a eexcellent safety profile, it did not reach statistical significance for the study primary endpoint for the overall study population
. However in the older group >75yrs, there appears to be a slight benefit - a statistically significant 40% did not show disease progression compared with 22% in placebo. Other small benefits were not statistically significant.

They could do a larger study to get more statistical power for a longer period. 9 months is not very long to study Alzheimer treatment.

Consequently The phase 3 trial has been suspended and funding for it apparently withdrawn, and they may or may not be doing one for that older cohort.
Lecanemab can cause brain swelling or bleeding as can donenemab. Xanamem has ongoing OLE studies for trial participants.
 
@prozac

It appears Xanamem is undergoing Phase 2 trials
There is still a long way to go

The big Phase 3 trial - where they test it on thousands of people is yet to be undertaken

There is another AD trial drug called Lecanemab (an antibody against the amyloid) which took, I think 5 years, for Phase 3. It is now approved by the TGA but not by the PBS meaning it costs about $40K a year.

Typically a Phase 3 might take 3-5 years, then 1 year for TGA approval and another year for PBS approval for concessional pricing.

Based on a quick look Specifically for Xanamem, it appears that the data suggest that while it has a eexcellent safety profile, it did not reach statistical significance for the study primary endpoint for the overall study population
. However in the older group >75yrs, there appears to be a slight benefit - a statistically significant 40% did not show disease progression compared with 22% in placebo. Other small benefits were not statistically significant.

They could do a larger study to get more statistical power for a longer period. 9 months is not very long to study Alzheimer treatment.

Consequently The phase 3 trial has been suspended and funding for it apparently withdrawn, and they may or may not be doing one for that older cohort.
And if "follow the money " is relevant, that company's shares are down >80% today on large turnover.
 
Read our AFF credit card guides and start earning more points now.

AFF Supporters can remove this and all advertisements

Become an AFF member!

Join Australian Frequent Flyer (AFF) for free and unlock insider tips, exclusive deals, and global meetups with 65,000+ frequent flyers.

AFF members can also access our Frequent Flyer Training courses, and upgrade to Fast-track your way to expert traveller status and unlock even more exclusive discounts!

AFF forum abbreviations

Wondering about Y, J or any of the other abbreviations used on our forum?

Check out our guide to common AFF acronyms & abbreviations.
Back
Top